Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.
Conley AP, Roland CL, Bessudo A, Gastman BR, Villaflor VM, Larson C, Reid TR, Caroen S, Oronsky B, Stirn M, Williams J, Burbano E, Coyle A, Barve MA, Wagle N, Abrouk N, Kesari S. Conley AP, et al. Among authors: wagle n. Cancer Gene Ther. 2024 Apr;31(4):517-526. doi: 10.1038/s41417-023-00720-0. Epub 2023 Dec 25. Cancer Gene Ther. 2024. PMID: 38146006 Free PMC article. Clinical Trial.
Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas.
Kesari S, Wojcinski A, Pabla S, Seager RJ, Gill JM, Carrillo JA, Wagle N, Park DJ, Nguyen M, Truong J, Takasumi Y, Chaiken L, Chang SC, Barkhoudarian G, Kelly DF, Juarez TM. Kesari S, et al. Among authors: wagle n. Oncoimmunology. 2024 Dec 31;13(1):2432728. doi: 10.1080/2162402X.2024.2432728. Epub 2024 Nov 21. Oncoimmunology. 2024. PMID: 39572979 Free PMC article. Clinical Trial.
A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features.
Klughammer J, Abravanel DL, Segerstolpe Å, Blosser TR, Goltsev Y, Cui Y, Goodwin DR, Sinha A, Ashenberg O, Slyper M, Vigneau S, Jané-Valbuena J, Alon S, Caraccio C, Chen J, Cohen O, Cullen N, DelloStritto LK, Dionne D, Files J, Frangieh A, Helvie K, Hughes ME, Inga S, Kanodia A, Lako A, MacKichan C, Mages S, Moriel N, Murray E, Napolitano S, Nguyen K, Nitzan M, Ortiz R, Patel M, Pfaff KL, Porter CBM, Rotem A, Strauss S, Strasser R, Thorner AR, Turner M, Wakiro I, Waldman J, Wu J, Gómez Tejeda Zañudo J, Zhang D, Lin NU, Tolaney SM, Winer EP, Boyden ES, Chen F, Nolan GP, Rodig SJ, Zhuang X, Rozenblatt-Rosen O, Johnson BE, Regev A, Wagle N. Klughammer J, et al. Among authors: wagle n. Nat Med. 2024 Nov;30(11):3236-3249. doi: 10.1038/s41591-024-03215-z. Epub 2024 Oct 30. Nat Med. 2024. PMID: 39478111 Free PMC article.
CDK4/6 Inhibitor Efficacy in ESR1-Mutant Metastatic Breast Cancer.
Lloyd MR, Brett JO, Carmeli A, Weipert CM, Zhang N, Yu J, Bucheit L, Medford AJ, Wagle N, Bardia A, Wander SA. Lloyd MR, et al. Among authors: wagle n. NEJM Evid. 2024 May;3(5):EVIDoa2300231. doi: 10.1056/EVIDoa2300231. Epub 2024 Apr 23. NEJM Evid. 2024. PMID: 38815172
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Abdou Y, Riley EC, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block CC, Ko N, Partridge AH, Chen WY, DeMeo M, Attaya V, Okpoebo A, Alberti J, Liu Y, Gauthier E, Burstein HJ, Regan MM, Tolaney SM. Mayer EL, et al. Among authors: wagle n. J Clin Oncol. 2024 Jun 10;42(17):2050-2060. doi: 10.1200/JCO.23.01940. Epub 2024 Mar 21. J Clin Oncol. 2024. PMID: 38513188 Clinical Trial.
199 results